CorMedix (CRMD) Income from Non-Controlling Interests (2024 - 2026)
CorMedix (CRMD) posted Income from Non-Controlling Interests of -$13.9 million for Q4 2025, up 87.16% sequentially from -$108.6 million in Q3 2025, and down 3.48% YoY from -$14.4 million in Q4 2024.
CorMedix (CRMD) Income from Non-Controlling Interests (2024 - 2026) Analysis & Trends
CorMedix has reported Income from Non-Controlling Interests for 2 years, with the latest figure at -$13.9 million in Q4 2025.
- Quarterly Income from Non-Controlling Interests fell 3.48% year-over-year to -$13.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was -$163.0 million (down 1008.75% YoY) and the FY2025 annual result came in at -$163.0 million, down 1008.75% from the prior year.
- Income from Non-Controlling Interests climbed to -$13.9 million in Q4 2025 per CRMD's latest filing, from -$108.6 million in the prior quarter.
- Over five years, Income from Non-Controlling Interests peaked at $14.5 million in Q1 2024 and troughed at -$108.6 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | - |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | - |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | - |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | - |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | - |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | - |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | 63.60 Mn |
| 10 | CorMedix | 645.20 Mn | 388.51 Mn | 77.13 Mn | -25.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -25.99 Mn |
| Dec 31, 2025 | -13.94 Mn |
| Sep 30, 2025 | -108.57 Mn |
| Jun 30, 2025 | -19.82 Mn |
| Mar 31, 2025 | -20.64 Mn |
| Dec 31, 2024 | -13.47 Mn |
| Sep 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 14.15 Mn |
| Mar 31, 2024 | 14.48 Mn |